Safety and Efficacy of the SurVeil Drug-Coated Balloon

    Not Recruiting
  • End date
    Apr 19, 2024
  • participants needed
  • sponsor
    SurModics, Inc.
Updated on 7 July 2022
Shawn K Fuller, BS
Primary Contact
St. Elizabeth's Medical Center (2.0 mi away) Contact
+62 other location
peripheral arterial diseases
transluminal angioplasty


To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.


TRANSCEND is a prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the IN.PACT Admiral DCB, and followed for 60 months.

Condition Peripheral vascular disease, peripheral arterial disease, Femoropopliteal Artery Occlusion
Treatment Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
Clinical Study IdentifierNCT03241459
SponsorSurModics, Inc.
Last Modified on7 July 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note